1. The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy
- Author
-
Sally A Ingham, Quan Dong Nguyen, Aniruddha Agarwal, Keegan A. Harkins, and Diana V. Do
- Subjects
0301 basic medicine ,Genotype ,Genetic enhancement ,Diabetic macular edema ,Legal blindness ,Pharmacology ,Bioinformatics ,Polymorphism, Single Nucleotide ,Macular Edema ,Epigenesis, Genetic ,03 medical and health sciences ,0302 clinical medicine ,Genetics ,medicine ,Humans ,Macular edema ,Genetic Association Studies ,Diabetic Retinopathy ,business.industry ,Genetic Therapy ,Diabetic retinopathy ,medicine.disease ,030104 developmental biology ,Pharmacogenetics ,Pharmacogenomics ,Retinal vasculopathy ,030221 ophthalmology & optometry ,Molecular Medicine ,business - Abstract
Diabetic retinopathy (DR) and its complications such as diabetic macular edema continue to remain a major cause for legal blindness in the developed world. While the introduction of anti-tVEGF agents has significantly improved visual outcomes of patients with DR, unpredictable response, largely due to genetic polymorphisms, appears to be a challenge with this therapy. With advances in identification of various genetic biomarkers, novel therapeutic strategies consisting of gene transfer are being developed and tested for patients with DR. Application of pharmacogenetic principles appears to be a promising futuristic strategy to attenuate diabetes-mediated retinal vasculopathy. In this comprehensive review, data from recent studies in the field of pharmacogenomics for the treatment of DR have been provided.
- Published
- 2016
- Full Text
- View/download PDF